Hemoglobin Inhibitors
3 drugsAbout Hemoglobin
Hemoglobin is an iron-containing protein in red blood cells responsible for oxygen transport throughout the body. Its primary function is to bind oxygen in the lungs and deliver it to tissues, facilitating cellular respiration. Hemoglobin's structure and function make it susceptible to modification by various compounds.
Hemoglobin is a drug target due to its role in oxygen delivery and susceptibility to modification. Currently, there is no genetic evidence directly linking hemoglobin to specific diseases. However, modulating oxygen binding or preventing hemoglobin-related toxicity offers therapeutic potential.
Three FDA-approved drugs, including SODIUM NITRITE, SODIUM THIOSULFATE, and NITHIODOTE, target hemoglobin. All three drugs are small molecules and are marketed by HOPE PHARMS, addressing critical medical conditions outside common therapeutic areas.
Top Hemoglobin Drugs
HOPE PHARMS is the only company with approved drugs targeting hemoglobin.
The market's low competition may present an opportunity for new entrants.
Hemoglobin Drug Modality Landscape
Modalities
Routes of Administration
Hemoglobin is druggable by small molecules, though no oral formulations are currently approved.
Exploring alternative modalities like antibodies or peptides could provide a competitive advantage.
Hemoglobin Clinical Trials 64 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Hemoglobin. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 18 | 11 | 5 | 2 | 69% |
| Phase 2 | 37 | 26 | 8 | 3 | 76% |
| Phase 3 | 7 | 1 | 3 | 3 | 25% |
| Phase 4 | 2 | 1 | 1 | 0 | 50% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Hemoglobin Drug Approval Timeline (1992 - 2012)
The first drug targeting hemoglobin was approved in 1992, with the most recent in 2012.
The approval timeline suggests a potentially saturated market with limited recent innovation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 3 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 3-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 45 (4 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Hemoglobin. A trial counts if an approved drug acting on Hemoglobin is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.